Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers

Scott Kopetz, MD, PhD1; Kenna R. Mills Shaw, PhD1; J. Jack Lee, MD1; Jiexin Zhang, MS1; Beate Litzenburger, PhD1; Vijaykumar Holla, PhD1; Walter Kinyua, MS1; Emily Broaddus1; Molly S. Daniels, MS1; Funda Meric-Bernstam, MD, PhD1; and Russell R. Broaddus, MD, PhD1

PURPOSE Smaller hotspot-based next-generation sequencing (NGS) panels have emerged to support standard of care therapy for patients with cancer. When standard treatments fail, it is unknown whether additional testing using an expanded panel of genes provides any benefit. The purpose of this study was to determine if larger sequencing panels that capture additional actionable genes, coupled with decision support, translates into treatment with matched therapy after frontline therapy has failed.

PATIENTS AND METHODS A prospective protocol accrued 521 patients with a wide variety of refractory cancers. NGS testing using a 46- or 50-gene hotspot assay, then a 409-gene whole-exome assay, was sequentially performed in a Clinical Laboratory Improvement Amendments–certified clinical laboratory. A decision-support team annotated somatic alterations in clinically actionable genes for function and facilitated therapeutic matching. Survival and the impact of matched therapy use were determined by Kaplan-Meier estimate, log-rank test, and Cox proportional hazards regression.

RESULTS The larger NGS panel identified at least one alteration in an actionable gene not previously identified in the smaller sequencing panel in 214 (41%) of 521 of enrolled patients. After the application of decision support, 41% of the alterations in actionable genes were considered to affect the function of the gene and were deemed actionable. Forty patients (40 of 214 [19%]) were subsequently treated with matched therapy. Treatment with matched therapy was associated with significantly improved overall survival compared with treatment with nonmatched therapy (P = .017).

CONCLUSION Combining decision support with larger NGS panels that incorporate genes beyond those recommended in current treatment guidelines helped to identify patients who were eligible for matched therapy while improving overall treatment selection and survival. This survival benefit was restricted to a small subset of patients.

INTRODUCTION Targeted sequencing of individual genes to guide therapy has become the standard of care for several different cancer types, including colorectal cancer (KRAS, BRAF, and NRAS), lung cancer (KRAS and EGFR), melanoma (BRAF), GI stromal tumor (KIT), and gliomas (IDH1 and IDH2). With current clinical molecular diagnostics, sequencing is faster, uses less tumor DNA, and costs less when genes are multiplexed into small next-generation sequencing (NGS) panels. Historically, the focus was often on the identification of mutations found in hotspots—areas of the genome where known drivers are frequently mutated, many of which can be mapped to therapeutic intervention. These panels typically emphasize genes that are recommended by cancer treatment guidelines.

An emerging utility of NGS is the screening of other types of cancers for mutations in clinically actionable genes that can be targeted therapeutically. Such treatment approaches are associated with improved survival in retrospective analyses screening,1 prospective trials,2-4 and meta-analyses,5-7 but this approach is not universally embraced.8,9 An important issue in these studies is the low number of patients who benefit from this approach. Reasons for this include the low incidence of actionable alterations, ineffective drugs for some targets, limited number of open slots in trials, and an unwillingness to enroll in
a trial. Limited access to targeted therapy trials is an issue, as some trials enroll only certain tumor types or are only active in a few geographic sites.

In patients with advanced cancer that is refractory to standard treatment, any benefit gained from the detection of mutations in clinically actionable genes beyond those detected using focused hotspot sequencing panels remains unknown. Hotspot-focused NGS panels fail to robustly identify copy number alterations or mutations that are found outside commonly altered loci, which would represent an advantage of larger NGS panels. The goal of our institutional initiative was to systematically determine the nature of the novel alterations identified in patients for which we previously had sequencing data from a small sequencing panel. We sought to determine if those alterations could be used to place additional patients into matched targeted therapy treatment regimens.

PATIENTS AND METHODS

Patient Selection

Patients were prospectively enrolled in an institutional review board–approved institutional protocol (PA14-0099) between May 7, 2014, and October 5, 2015. Enrollment criteria included the following: adult patient with pathologic documentation of a single solid tumor malignancy; completed frontline treatment and any standard treatments that extended life by at least 3 months; Eastern Cooperative Oncology Group performance status of 0 or 1; no active brain metastases; and completed tumor testing using a smaller sequencing panel and either disease progression on a matched therapy that targeted a previously identified actionable finding or no clinically actionable mutations detected.

Molecular Assays and Decision Support

Hotspot mutation testing was primarily performed on archival formalin-fixed, paraffin-embedded primary and metastatic cancers acquired during the course of routine clinical care using a 46- or 50-gene NGS panel described previously [10] (actionable genes summarized in the Data Supplement). Subsequent testing used a larger NGS panel that consisted of the entire coding regions of 409 cancer-related genes with methodologies previously detailed [11] (actionable genes and details of larger NGS panel provided in the Data Supplement). The protocol did not provide for image-guided biopsies of the most recent metastasis for testing; median time since tissue acquisition to NGS was 467 days (Appendix Fig A1). Relevant germline findings were reported to the referring oncologist. [12] For comparisons with protocol patients, The Cancer Genome Atlas (TCGA) data—gene mutations and gene amplifications—for the same 409 genes from 316 ovarian high-grade serous carcinomas, 212 colorectal adenocarcinomas, and 230 lung adenocarcinomas were extracted using cBioPortal.org. For patients with colorectal cancer, mismatch repair was assessed as part of routine clinical care. [13] Somatic mutations and amplifications that were reported for each patient were reviewed by the Precision Oncology Decision Support Team. [14,15] This involved annotation for function and potential clinical trial matching for actionability. Actionability was limited to the following: genes for which a drug is available that directly or indirectly targets proteins and/or signaling pathways activated as a result of alterations in the gene, and whether there is preclinical or clinical evidence that demonstrates that genomic alterations in the gene are drivers of tumorigenesis and/or confer sensitivity to targeted agents. Somatic alterations in actionable genes were classified
TABLE 1. Characteristics for Patients Enrolled and Tested in the Prospective Protocol

| Characteristic                      | No. (%) |
|------------------------------------|---------|
| **Sex**                            |         |
| Female                             | 270 (51.8) |
| Male                               | 251 (48.2) |
| All                                | 521 (100.0) |
| **Performance status**             |         |
| 0                                  | 131 (25.1) |
| 1                                  | 384 (73.7) |
| 2                                  | 5 (1.0) |
| Missing                            | 1 (0.2) |
| All                                | 521 (100.0) |
| **Race**                           |         |
| Asian                              | 26 (5.0) |
| Black                              | 37 (7.1) |
| White                              | 391 (75.0) |
| Hawaiian/Pacific Islander          | 5 (1.0) |
| Hispanic                           | 54 (10.4) |
| Other                              | 4 (0.8) |
| Unknown                            | 4 (0.8) |
| All                                | 521 (100.0) |
| **Tumor type**                     |         |
| Bladder                            | 16 (3.1) |
| Breast                             | 42 (8.1) |
| Colorectal                         | 78 (15.0) |
| Endometrial                        | 16 (3.1) |
| Gastric/gastroesophageal junction  | 12 (2.3) |
| Germ cell tumor                    | 12 (2.3) |
| Head and neck                      | 43 (8.2) |
| Lung                               | 34 (6.5) |
| Neuroendocrine                     | 17 (3.3) |
| Others                             | 67 (12.9) |
| Ovarian                            | 43 (8.2) |
| Prostate                           | 14 (2.7) |
| Renal                              | 29 (5.6) |
| Sarcoma                            | 72 (13.8) |
| Thyroid                            | 26 (5.0) |
| All                                | 521 (100.0) |
| **Age, years**                     |         |
| ≤ 20                               | 7 (1.3) |
| 20-30                              | 25 (4.8) |
| 30-40                              | 43 (8.2) |
| 40-50                              | 100 (19.2) |
| 50-60                              | 147 (28.2) |
| 60-70                              | 138 (26.5) |
| > 70                               | 61 (11.7) |
| All                                | 521 (100.0) |

for their functional and therapeutic significance using published literature, our internal functional genomics platform, \(^{16,17}\) and interpretations of the impact of the mutation on the basis of location within the protein structure. Variants were annotated as actionable, not actionable, or of unknown actionability (Data Supplement). For the smaller 46- and 50-gene NGS panel, 34 and 38 genes, respectively, were considered actionable, whereas for the larger 409-gene NGS panel, 96 genes were actionable (Data Supplement).

**Statistical Analysis**

Study sample size was dictated by the capacity of the Clinical Laboratory Improvement Amendments–certified clinical molecular diagnostics laboratory that performed the 409-gene NGS panel, estimated to be 25 cases per week. With a target of 600 patients, it was determined a priori that the rate of identification of alterations in actionable genes could be estimated with a standard error of no more than 0.02. We used Fisher’s exact test to assess whether the gene mutation frequency was significantly different between protocol patients with colorectal adenocarcinoma, lung adenocarcinoma, or ovarian high-grade serous carcinoma and corresponding TCGA data sets. The probability of overall survival was determined by Kaplan-Meier estimate, and we used a log-rank test to assess the statistical significance of the difference between patient groups. To evaluate the effect of clinical variables on overall survival, we performed multivariable survival analysis using a Cox proportional hazards regression model that included variables that were significant (\( P < .05 \)) in a univariable analysis.

**RESULTS**

**Characteristics of the Patient Population Enrolled in the Protocol**

A total of 675 patients were enrolled, with large-panel testing completed in 569 patients. Patient death, declination to return for treatment, and insufficient tissue were the primary reasons for not completing the 409-gene panel NGS testing. Five hundred twenty-one patients who received at least 6 months of follow-up or who died within 6 months were included in the analysis (Appendix Fig A2). Colorectal cancer, sarcoma, head and neck cancer, ovarian cancer, and breast cancer were the most frequently represented cancers in the cohort (Table 1), but the protocol enrolled patients with a broad spectrum of cancer types.

**Sequencing Results**

Once material was received by the molecular diagnostics laboratory, a median of 13 days passed before the molecular reports were finalized and entered into the electronic medical record (Appendix Fig A3). Of the 521 patients, 71% entered the study without any mutations in actionable genes identified in the smaller NGS panel that

---

**Clinical Benefit of Larger NGS Panels**
would allow for enrollment in a matched targeted therapy clinical trial. Of the 521 patients who were tested with the 409-gene NGS assay, 214 (41%) had at least one tumor alteration in an actionable gene that was not identified in a prior assay using a smaller NGS panel (Figs 1A and 1B). Full 409-gene NGS assay results are summarized for all patients in the Data Supplement. Ten percent of these patients had amplifications in actionable genes that were not detectable in the smaller NGS panels. Not counting the sequencing results from the smaller panel, the mean number of alterations detected in actionable genes in the 409-gene panel was 1.0 (range, 0 to 66; Fig 1C). After the application of decision support, 201 (41%) of 495 alterations in actionable genes were considered to affect the function of the gene and were deemed actionable (mean per patient, 0.4; range, 0 to 5; Fig 1D). The rate of detection of an alteration in an actionable gene with additional testing was dependent on tumor type, with low rates observed in thyroid and ovarian cancers (Fig 2A). Alterations in a variety of actionable genes from the 409-gene panel were identified, with the most common mutations in genes NF1, MDM2, ATM, KDR, NOTCH2, ERBB2, MTOR, and PTEN (Fig 2B).

Matching Tested Patients to Targeted Therapy

Of the 214 patients who had alterations in actionable genes in the large NGS platform that were not detected in the previous small-panel NGS testing, 40 (19%) were matched...
to a targeted therapy on the basis of their molecular profile within 6 months of receiving test results (Data Supplement). A total of 108 patients in the cohort were treated with unmatched therapy after the completion of large NGS panel testing. These patients had mutations in actionable genes that were classified as actionable, potentially actionable, or a variant of unknown significance but the oncologist chose a therapy that was not a match to the gene alterations found. Reasons for not treating with matched therapy protocols were similar to those from a previously reported patient population and included declining performance status, a desire to seek treatment closer to home, or an oncologist who did not consider the gene mutation clinically actionable or the targeted therapy sufficiently active in the given tumor type (Data Supplement).

**Decision Support**

Decision support was critical as alterations were detected in a number of actionable genes that were less familiar to oncologists, and the availability of matching clinical trials varied during the study period. As previously mentioned, 41% of detected alterations in actionable genes were classified as actionable alterations. This is in contrast to the 2% of alterations that were classified as having no impact on function. Within this context, 44% of alterations in actionable genes were classified as variants of unknown significance. The remaining 13% were from one patient with 66 mutations in actionable genes. Given the hypermutated nature of this patient’s tumor, it was felt that none of the mutations would act as a driver or represented a good target for matched therapy; thus, they were not annotated (Fig 3A). Less than one half of actionable alterations were previously reported in the peer-reviewed literature. For the remainder, actionability was deduced from the type of mutation present.

Mutation burden varied substantially in the patient population. Not counting the sequencing results from the smaller panel, nearly 70% of tumor alterations were identified in patients with tumors that were found to be in the top quartile of overall tumor mutation burden. After the

FIG 2. (A and B) Summary of alterations per tumor type (A) and specific genes in which alterations were identified (B). (A) Stacked bar chart shows the percent of cases for each broad class of tumor type listed with 0, 1, 2, or 3 or more alterations in actionable genes not detected in the smaller testing panel. Data are shown for tumor types in which at least 10 patient tumors were sequenced. Total alterations include both mutations and gene amplifications. (B) Alterations were found across a broad spectrum of potentially actionable genes. GE, gastroesophageal.
application of decision support, the number of actionable alterations was poorly correlated with mutation burden, as less than 50% of actionable alterations in actionable genes are in the top quartile of mutation load (Fig 3B). Thus, tumor mutation burden was not a good predictor of the presence of a clinically actionable alteration.

**Patient Outcomes**

Neither the number of overall gene alterations in the tumor, nor the presence of alterations in actionable genes significantly influenced patient survival (Figs 4A and 4B). Overall, most patients had poor survival (Fig 4C); however, patients with an alteration in an actionable gene who were treated with matched targeted therapy had significantly improved survival compared with the remainder of the cohort (Fig 4C) and patients who were treated with nonmatched therapy (Fig 4D; P = .017). Individual survival analyses among the most common tumor types represented in the protocol did not identify a specific cancer type that was significantly associated with improved survival (Fig 5). Among the nine genes that were commonly altered in protocol patients, none was associated with survival (Fig 5). Survival was assessed by manual curation of the medical record along with the date when a patient was last known to be alive as documented by a physician note or date of death provided by obituary, tumor registry, or reported by a family member. This study is limited by the lack of randomization; however, comparison of matched and unmatched patients helps to minimize concerns related to comorbidities or declining performance status as an explanation for the differences in outcomes observed in Figures 4C and 4D, as all patients in this analysis received another line of therapy, including participation in clinical trials.

Two patients were found to have deleterious germline mutations that were not previously known to the patient or oncologist—patient management was not altered in either case. One patient with optic glioma and a history of early-stage endometrial cancer had an MSH6 germline mutation.
A second patient with pleomorphic liposarcoma had a TP53 germline mutation.

Characteristics of Protocol Patients Compared With TCGA

Given that an eligibility criterion for enrollment was recurrence after frontline therapy, the molecular testing profiles for this patient cohort may differ from those previously published. TCGA did not select for patients with advanced cancers; therefore, we compared mutation frequencies in our cohort with those of the TCGA for colorectal adenocarcinoma, lung adenocarcinoma, and ovarian high-grade serous carcinoma.19-21 These three cancers were examined because of their relatively homogeneous histology and sufficient representation in the study. For colorectal cancer, KRAS mutation frequency was higher in our patient population, which was consistent with their resistance to epidermal growth factor receptor–directed therapy22 (Data Supplement). Protocol patients also had a significantly higher incidence of TP53 mutations (72% v 52%; \( P = .004 \); data not shown). Only 3% of protocol colorectal cancers were microsatellite instability–high compared with 13% in TCGA. This is consistent with prior reports on the good prognosis of this subgroup.23 For ovarian high-grade serous carcinoma, alterations in actionable genes CCNE1 (20%), NF1 (12%), PIK3CA (18%), and PTEN (8%) were the most common in TCGA; however, only one protocol patient with ovarian cancer had a CCNE1 amplification, whereas no alterations
were observed in the other genes (Data Supplement). For lung adenocarcinoma, alterations in EGFR, KRAS, and BRAF were comparable between protocol patients and TCGA (data not shown). Only two clinically actionable genes—CDKN2A and CDKN2B—had lower frequencies of alteration in protocol patients with lung adenocarcinoma (Data Supplement).

**DISCUSSION**

Survival for the overall cohort was poor in this institution-wide prospective protocol that enrolled patients with advanced solid tumor malignancies refractory to treatment. For 41% of these patients, we identified an alteration in a clinically actionable gene that was not detected by previous small-panel testing. With the aid of systematic decision support, this led to patients being directed to matched targeted therapy treatment regimens. Analysis of this enhanced gene set coupled with a targeted therapeutic approach was associated with improved survival. The overall utility of single—as opposed to sequential small-panel, then large-panel testing—large-panel NGS testing combined with decision support can be estimated by combining the 11% enrollment in clinical trials from our prior 46- and 50-gene panel study with the 8% derived from the incremental addition of the large-panel testing in this study. Although the result compares favorably with that from prior cohorts, such as MOSCATO (Molecular Screening for Cancer Treatment Optimization; 7%), ATTACC (Assessment of Targeted Therapies Against Colorectal Cancer; 20%), and SAFIR01 (High-Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Therapies; 13%), it highlights the fact that the

---

**FIG 5.** (A-J) Kaplan-Meier plots for overall survival for nine actionable genes commonly altered in clinical protocol patients (A-I) and for the most common cancer types represented in the protocol (J). No cancer type or alteration in a specific gene had a significant impact on patient survival. HN, head and neck.
matched targeted therapy approach still only benefits a small percentage of patients with cancer. Testing was performed on archival tissue rather than on a biopsy of the most recent metastatic site. As metastases can accumulate mutations over time, this represents another potential reason for limited patient benefit.

With increasing gene targets and matched drugs, it is becoming increasingly difficult for an individual physician to reasonably interpret the molecular findings from larger NGS panels. The importance of decision support in a comprehensive precision medicine strategy is highlighted by the fact that less than one half of actionable alterations in a comprehensive precision medicine strategy is highlighted by the fact that less than one half of actionable alterations in actionable genes had been reported previously in the literature. Over time, at least some of these variants of undetermined significance may be found to be activating mutations after they are examined in functional assays. Examples of variants that have been reclassified as activating mutations in a functional genomics platform include PDGFR A K385M, PIK3CA E110del, and RET D627N. Whereas decision support may be more readily available in academic practice, there are a number of publicly available and commercial databases that can provide such support. Publicly available options include My Cancer Genome, The Jackson Laboratory Clinical Knowledge Database, and OncoKB. Commercial providers include N-of-One, Molecular Health, and GenomOncology. The challenge to the community oncologist is deciphering which bioinformatics pipeline is most reliable. The reliability of quality decision support is crucial as patients with advanced cancers have a finite lifespan.

Patients with advanced cancers that are refractory to standard therapy may have mutational frequencies of individual genes that differ from published frequencies derived from unselected patients. This was apparent in patients with colorectal cancer and ovarian high-grade serous carcinoma in whom frequencies likely reflected a bias toward more clinically aggressive or treatment-resistant tumor biology. For example, frontline treatment of ovarian cancer is platinum-based chemotherapy; it is possible that, by selecting for patients with platinum-resistance, the protocol also selected for patients with ovarian cancers with therapy-driven alterations in the molecular landscape. The phenomenon is supported by the comparison of survival populations from stage-matched patients in TCGA and clinical trials, where patient survival from clinical trials was substantially lower.5 Patients with advanced cancers may have higher incidences of mutations associated with other forms of treatment resistance, such as EGFR T790M and ESR1 mutations.28 The potentially unique molecular features in patients with advanced, chemotherapy-resistant cancers may represent one factor that contributes to the low success rate of the matched targeted therapy approach.

Treatment directed against actionable genes remains suboptimal. Pathways that were previously thought to be universally targetable have proven to be difficult to treat, such as the phosphatidylinositol 3-kinase/AKT pathway,29 or subject to variation in results by tumor type, such as BRAFV600E or HER2/3 mutations.31,32 In protocol patients, we were unable to ascertain any strong individual signals of activity for particular alterations in specific tumor types in part because of insufficient numbers of patients.

In conclusion, these results demonstrate the utility of large-panel NGS testing when combined with decision support. The derived benefit is realized in only a small subset of patients. Future efforts should emphasize high-quality and timely decision support and minimize barriers to patient enrollment, with the ultimate goal of broadly delivering precision medicine to patients with solid tumor malignancies. A critical step will involve identifying which combination of tumor type and alterations in actionable gene(s) is most efficacious when coupled with the most appropriate targeted therapeutics.

AFFILIATION

1University of Texas MD Anderson Cancer Center, Houston, TX

CORRESPONDING AUTHOR

Russell R. Broaddus, MD, PhD, Department of Pathology, Unit 85, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; Twitter: @MDAndersetNews; e-mail: rbroaddus@mdanderson.org.

SUPPORT

Supported, in part, by undesignated donor funds from the MD Anderson annual funds program provided by the Provost’s office, Khalifa Bin Zayed Al Nahyan Foundation, Cancer Prevention Research Institute of Texas Grant No. RP150535 (F.M.-B.), National Center for Advancing Translational Sciences Grant No. UL1-TR000371 (Center for Clinical and Translational Sciences), and the Cancer Center Support Grant, MD Anderson, National Cancer Institute Grant No. CA016672.

AUTHOR CONTRIBUTIONS

Conception and design: Scott Kopetz, Kenna R. Mills Shaw, J. Jack Lee, Russell R. Broaddus

Financial support: Kenna R. Mills Shaw, Funda Meric-Bernstam

Administrative support: Scott Kopetz, Kenna R. Mills Shaw, Funda Meric-Bernstam

Provision of study materials or patients: Scott Kopetz, Kenna R. Mills Shaw, Funda Meric-Bernstam

Collection and assembly of data: Scott Kopetz, Kenna R. Mills Shaw, J. Jack Lee, Beate Litzenburger, Walter Kinyua, Emily Broaddus, Molly S. Daniels, Funda Meric-Bernstam, Russell R. Broaddus

Data analysis and interpretation: Kenna R. Mills Shaw, J. Jack Lee, Jixian Zhang, Beate Litzenburger, Vijnakumar Holia, Molly S. Daniels, Funda Meric-Bernstam, Russell R. Broaddus

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

1University of Texas MD Anderson Cancer Center, Houston, TX

JCO Precision Oncology
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/wc or po.ascopubs.org/site/ifc.

Scott Kopetz
Stock and Other Ownership Interests: MolecularMatch, Navire Consulting or Advisory Role: Roche, Genentech, EMD Serono, Merck, Karyopharm Therapeutics, Amal Therapeutics, Navire Pharma, Symphogen, Holy Stone, Biocrates, Amgen, Novartis Research Funding: Amgen (Inst), Sanofi (Inst), Biocrates (Inst), Guardant Health (Inst), Array BioPharma (Inst), Genentech (Inst), EMD Serono (Inst), MedImmune (Inst), Novartis (Inst)

J. Jack Lee
Consulting or Advisory Role: AbbVie

REFERENCES
1. Tsimeridou AM, Islander NG, Hong DS, et al: Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative. Clin Cancer Res 18:6373-6383, 2012
2. Massard C, Michiels S, Ferté C, et al: High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 trial. Cancer Discov 7:586-595, 2017
3. Radochov M, Kiel PJ, Nance SM, et al: Clinical benefit of a precision medicine-based approach for guiding treatment of refractory cancers. Oncotarget 7:56491-56500, 2016
4. Wheler JJ, Janku F, Naing A, et al: Cancer therapy directed by comprehensive genomic profiling: A single center study. Cancer Res 76:3690-3701, 2016
5. Jardim DL, Schwaederle M, Wei C, et al: Impact of a biomarker-based strategy on oncology drug development: A meta-analysis of clinical trials leading to FDA approval. J Natl Cancer Inst 107:dx253, 2015
6. Schwaederle M, Zhao M, Lee JJ, et al: Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials. J Clin Oncol 33:3817-3825, 2015
7. Schwaederle M, Zhao M, Lee JJ, et al: Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: A meta-analysis. JAMA Oncol 2:1452-1459, 2016
8. Prasad V: Perspective: The precision-oncology illusion. Nature 537:563, 2016
9. Tannock IF, Hickman JA: Limits to precision cancer medicine. N Engl J Med 376:96-97, 2017
10. Singh RR, Patel KP, Routbort MJ, et al: Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn 15:607-622, 2013
11. Singh RR, Patel KP, Routbort MJ, et al: Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer 111:2014-2023, 2014
12. Merci-Bernstam F, Brusco L, Daniels M, et al: Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol 27:795-800, 2016
13. Bartley AN, Luthra R, Saraiya DS, et al: Identification of cancer patients with Lynch syndrome: Clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res (Phila) 5:320-327, 2012
14. Johnson A, Zeng J, Bailey AM, et al: The right drugs at the right time for the right patient: The MD Anderson precision oncology decision support platform. Drug Discov Today 20:1433-1438, 2015
15. Merci-Bernstam F, Johnson A, Holla V, et al: A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 107:djv098, 2015
16. Cheung LW, Yu S, Zhang D, et al: Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell 26:479-494, 2014
17. Liang H, Cheung LW, Li J, et al: Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 22:2120-2129, 2012
18. Merci-Bernstam F, Brusco L, Shaw K, et al: Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol 33:2753-2762, 2015
19. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337, 2012
20. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011 [Erratum: Nature 490:298, 2012]
21. Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543-560, 2014 [Errata: Nature 514:262, 2014; Nature 559:E12, 2018]
22. Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995, 2006

Beate Litzenburger
Employment: Qiagen

Funda Merci-Bernstam
Honorary: Sumitomo Group, Dialectica Consulting or Advisory Role: Genentech, Inflection Biosciences, Pieris Pharmaceuticals, Clearlight Diagnostics, Darwin Health, Samsung Bioepis, Spectrum Pharmaceuticals, Aduro Biotech, Origimed, Xencor, Debiopharm Group Research Funding: Novartis, AstraZeneca, Taiho Pharmaceutical, Genentech, Calithera Biosciences, Debiopharm Group, Bayer, Aileron Therapeutics, Puma Biotechnology, CytoMx Therapeutics, Jounce Therapeutics, Zymeworks, Curis, Pfizer, eFFECTOR Therapeutics, AbbVie, Boehringer Ingelheim (I), Guardant Health (Inst)

No other potential conflicts of interest were reported.
23. Koopman M, Kortman GA, Mekenkamp L, et al: Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 100:266-273, 2009

24. Overman MJ, Morris V, Kee B, et al: Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol 27:1068-1074, 2016

25. André F, Bachelot T, Commo F, et al: Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: A multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 15:267-274, 2014

26. Ng PK-S, Li J, Jeong KJ, et al: Systematic functional annotation of somatic mutations in cancer. Cancer Cell 33:450-462.e10, 2018

27. Geifman N, Butte AJ: Do cancer clinical trial populations truly represent cancer patients? A comparison of open clinical trials to the cancer genome atlas. Pac Symp Biocomput 21:309-320, 2016

28. Hartmaier RJ, Albacker LA, Chmielecki J, et al: High-throughput genomic profiling of adult solid tumors reveals novel insights into cancer pathogenesis. Cancer Res 77:2464-2475, 2017

29. Mayer IA, Arteaga CL: The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med 67:11-28, 2016

30. Kopetz S, Desai J, Chan E, et al: Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 33:4032-4038, 2015

31. Hyman DM, Piha-Paul SA, Rodon J, et al: Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial. Cancer Res 76, 2016 (abstr PDS-05)

32. Hyman DM, Piha-Paul SA, Won H, et al: HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194, 2018
APPENDIX

FIG A1. Summary of time from tumor tissue acquisition (surgery or biopsy) to NGS testing. Q, quartile.
FIG A2. CONSORT diagram summarizing the progress of patients enrolled in the next-generation sequencing (NGS) protocol.
FIG A3. Summary of the turnaround time (in days) for large panel next-generation sequencing testing to be finalized once tissue was received by the clinical molecular diagnostics lab. Red line indicates median (13 days).